Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 205,416,992
  • Shares Outstanding, K 3,100,634
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • EBIT $ 9,201 M
  • EBITDA $ 14,588 M
  • 60-Month Beta 0.46
  • Price/Sales 4.05
  • Price/Cash Flow 12.21
  • Price/Book 5.01

Options Overview Details

View History
  • Implied Volatility 24.19% ( -4.79%)
  • Historical Volatility 20.56%
  • IV Percentile 69%
  • IV Rank 44.33%
  • IV High 34.77% on 10/31/24
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 13,313
  • Volume Avg (30-Day) 9,020
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 158,664
  • Open Int (30-Day) 164,295

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.06
  • Number of Estimates 6
  • High Estimate 1.21
  • Low Estimate 0.97
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +45.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.75 +3.92%
on 12/20/24
69.00 -3.98%
on 12/09/24
-1.80 (-2.65%)
since 12/03/24
3-Month
62.75 +5.58%
on 11/18/24
78.65 -15.77%
on 10/16/24
-11.68 (-14.99%)
since 10/03/24
52-Week
60.47 +9.56%
on 02/12/24
87.68 -24.44%
on 08/30/24
-2.07 (-3.03%)
since 01/03/24

Most Recent Stories

More News
Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't know...

AZN : 66.25 (+0.56%)
NVO : 87.65 (+0.15%)
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

ALLO : 2.16 (-1.82%)
NVDA : 144.47 (+4.45%)
IOVA : 7.65 (-1.80%)
AZN : 66.25 (+0.56%)
AMZN : 224.19 (+1.80%)
CLLS : 1.6750 (-7.46%)
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

For Immediate ReleasesChicago, IL – January 3, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

AZN : 66.25 (+0.56%)
JNJ : 144.19 (+0.12%)
LLY : 781.98 (+0.50%)
ABBV : 181.22 (+0.99%)
PFE : 26.59 (-0.08%)
Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

New York, New York--(Newsfile Corp. - January 2, 2025) - Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS...

AZN : 66.25 (+0.56%)
5 Large Drug Stocks to Keep An Eye On in the New Year

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services,...

AZN : 66.25 (+0.56%)
JNJ : 144.19 (+0.12%)
LLY : 781.98 (+0.50%)
ABBV : 181.22 (+0.99%)
PFE : 26.59 (-0.08%)
Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

BAYRY : 4.8550 (-1.72%)
AZN : 66.25 (+0.56%)
$SPX : 5,942.47 (+1.26%)
BBIO : 28.12 (-0.28%)
PFE : 26.59 (-0.08%)
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab...

AZN : 66.25 (+0.56%)
MRK : 99.14 (-0.03%)
PFE : 26.59 (-0.08%)
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY

This week, Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly’s LLY Zepbound for treating moderate-to-severe obstructive sleep...

AZN : 66.25 (+0.56%)
NVO : 87.65 (+0.15%)
LLY : 781.98 (+0.50%)
PFE : 26.59 (-0.08%)
SNY : 48.15 (-0.08%)
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

ONCY : 0.9599 (+3.24%)
AZN : 66.25 (+0.56%)
ABBV : 181.22 (+0.99%)
ONC.TO : 1.40 (+6.06%)
GSK : 33.47 (-1.41%)
CRDF : 4.70 (+10.33%)
Why IonQ Is the Best Quantum Computing Stock to Buy Right Now

Quantum computing represents the next frontier in computational power. Once developed, these systems could solve complex problems in drug development, financial modeling, and artificial intelligence (AI)...

MSFT : 423.35 (+1.14%)
GOOGL : 191.79 (+1.25%)
GOOG : 193.13 (+1.31%)
LMT : 481.82 (-0.09%)
ANSS : 338.38 (+0.69%)
AZN : 66.25 (+0.56%)
IONQ : 47.77 (+10.84%)
QTUM : 83.58 (+1.42%)
AMZN : 224.19 (+1.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 66.79
2nd Resistance Point 66.63
1st Resistance Point 66.44
Last Price 66.25
1st Support Level 66.09
2nd Support Level 65.93
3rd Support Level 65.74

See More

52-Week High 87.68
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
Last Price 66.25
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar